$OVID
Ovid Therapeutics Inc.

2019 Q3 Form 10-Q Financial Statement

#000156459019030178 Filed on August 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.200M $4.200M $5.100M
YoY Change 13.04% -17.65% 21.43%
% of Gross Profit
Research & Development $11.60M $9.117M $8.116M
YoY Change 35.73% 12.33% 33.6%
% of Gross Profit
Depreciation & Amortization $10.00K $9.000K $9.000K
YoY Change 42.86% 0.0% 35.24%
% of Gross Profit
Operating Expenses $16.77M $13.32M $13.21M
YoY Change 27.24% 0.85% 28.4%
Operating Profit -$16.77M -$13.32M -$13.21M
YoY Change 0.85% 28.4%
Interest Expense $100.0K $300.0K $300.0K
YoY Change -50.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $131.0K $265.0K $275.0K
YoY Change -38.79% -3.64% 587.5%
Pretax Income -$16.60M -$13.10M -$12.90M
YoY Change 27.69% 1.55% 26.47%
Income Tax
% Of Pretax Income
Net Earnings -$16.63M -$13.06M -$12.94M
YoY Change 28.33% 0.95% 26.22%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$431.2K -$338.5K -$518.1K
COMMON SHARES
Basic Shares Outstanding 38.69M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.90M $47.40M $62.60M
YoY Change -27.81% -24.28% -41.0%
Cash & Equivalents $37.91M $47.36M $22.54M
Short-Term Investments $0.00 $0.00 $40.10M
Other Short-Term Assets $1.200M $4.700M $2.600M
YoY Change -55.56% 80.77% 116.67%
Inventory
Prepaid Expenses
Receivables $0.00 $1.600M
Other Receivables $0.00 $0.00
Total Short-Term Assets $39.15M $53.61M $65.20M
YoY Change -29.14% -17.78% -39.24%
LONG-TERM ASSETS
Property, Plant & Equipment $72.24K $58.78K $100.0K
YoY Change -27.76% -41.23% 100.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $351.3K $270.9K $3.400M
YoY Change -93.11% -92.03% 1475.91%
Total Long-Term Assets $1.544M $1.301M $3.400M
YoY Change -70.0% -61.73% 388.63%
TOTAL ASSETS
Total Short-Term Assets $39.15M $53.61M $65.20M
Total Long-Term Assets $1.544M $1.301M $3.400M
Total Assets $40.69M $54.91M $68.60M
YoY Change -32.63% -19.96% -36.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.342M $2.048M $3.400M
YoY Change 16.12% -39.76% -4.8%
Accrued Expenses $4.682M $7.136M $4.100M
YoY Change -19.28% 74.04% 17.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.36M $9.184M $7.500M
YoY Change -0.37% 22.45% 6.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $300.0K $300.0K
YoY Change
Total Long-Term Liabilities $300.0K $300.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.36M $9.184M $7.500M
Total Long-Term Liabilities $300.0K $300.0K $0.00
Total Liabilities $10.65M $9.470M $7.500M
YoY Change 2.38% 26.27% 5.63%
SHAREHOLDERS EQUITY
Retained Earnings -$196.2M -$179.6M
YoY Change
Common Stock $226.2M $225.0M
YoY Change 19.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.05M $45.44M $61.12M
YoY Change
Total Liabilities & Shareholders Equity $40.69M $54.91M $68.60M
YoY Change -32.63% -19.96% -36.49%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$16.63M -$13.06M -$12.94M
YoY Change 28.33% 0.95% 26.22%
Depreciation, Depletion And Amortization $10.00K $9.000K $9.000K
YoY Change 42.86% 0.0% 35.24%
Cash From Operating Activities -$9.500M -$11.80M -$11.60M
YoY Change -5.94% 1.72% 96.61%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$100.0K
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $5.000M $5.000M
YoY Change -100.0% 0.0%
Cash From Investing Activities $0.00 $5.000M $4.900M
YoY Change -100.0% 2.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K -400.0K 100.0K
YoY Change 0.0% -500.0% -99.85%
NET CHANGE
Cash From Operating Activities -9.500M -11.80M -11.60M
Cash From Investing Activities 0.000 5.000M 4.900M
Cash From Financing Activities 100.0K -400.0K 100.0K
Net Change In Cash -9.400M -7.200M -6.600M
YoY Change -218.99% 9.09% -110.65%
FREE CASH FLOW
Cash From Operating Activities -$9.500M -$11.80M -$11.60M
Capital Expenditures $0.00 $0.00 -$100.0K
Free Cash Flow -$9.500M -$11.80M -$11.50M
YoY Change -5.0% 2.61% 94.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Shell Company
EntityShellCompany
false
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38693018
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
72088199
dei Entity File Number
EntityFileNumber
001-38085
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16022
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12915248
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26855633
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1350
dei Entity Address Address Line1
EntityAddressAddressLine1
1460 Broadway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 15044
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
465270895
dei Entity Address State Or Province
EntityAddressStateOrProvince
New York
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
646
dei Local Phone Number
LocalPhoneNumber
661-7661
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47361966
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36489618
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
5011034
CY2019Q2 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
1594437
CY2018Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
600104
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4650735
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2167391
CY2019Q2 us-gaap Assets Current
AssetsCurrent
53607138
CY2018Q4 us-gaap Assets Current
AssetsCurrent
44268147
CY2019Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
857868
CY2018Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
2797561
CY2019Q2 us-gaap Security Deposit
SecurityDeposit
113550
CY2018Q4 us-gaap Security Deposit
SecurityDeposit
122155
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
58775
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
69867
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
270947
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
391872
CY2019Q2 us-gaap Assets
Assets
54908278
CY2018Q4 us-gaap Assets
Assets
47649602
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2048130
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3755595
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7135687
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5088862
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9183817
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8844457
CY2019Q2 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
286562
CY2019Q2 us-gaap Liabilities
Liabilities
9470379
CY2018Q4 us-gaap Liabilities
Liabilities
8844457
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
3
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
38693
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
24654
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
224951943
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
191477598
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1829
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179552740
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152695278
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
45437899
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
38805145
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54908278
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47649602
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(C) Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.</font></p>
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1844205
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
98701
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
19892
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
61115857
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16590942
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4204771
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38693018
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24654114
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38693018
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24654114
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9117495
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8116385
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18454804
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5093311
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8920999
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10048615
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
13322266
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
13209696
us-gaap Operating Expenses
OperatingExpenses
27375803
us-gaap Operating Expenses
OperatingExpenses
26639557
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13322266
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13209696
us-gaap Operating Income Loss
OperatingIncomeLoss
-27375803
us-gaap Operating Income Loss
OperatingIncomeLoss
-26639557
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
264999
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
274556
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
518341
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
521662
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-13057267
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-12935140
us-gaap Net Income Loss
NetIncomeLoss
-26857462
us-gaap Net Income Loss
NetIncomeLoss
-26117895
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13057267
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12935140
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
19892
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1829
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13058617
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26133917
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30522028
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1642540
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
73104
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-13800195
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
57245801
CY2019Q2 ovid Underwriting Costs Of Offering
UnderwritingCostsOfOffering
1193
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1251908
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1350
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
83436503
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1794967
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12678
CY2018Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
62723
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-35914
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-13182758
us-gaap Share Based Compensation
ShareBasedCompensation
2894448
us-gaap Share Based Compensation
ShareBasedCompensation
3639173
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
145797
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
51692
ovid Accrued Interest And Accretion Of Discounts Short Term Investments
AccruedInterestAndAccretionOfDiscountsShortTermInvestments
12863
ovid Accrued Interest And Accretion Of Discounts Short Term Investments
AccruedInterestAndAccretionOfDiscountsShortTermInvestments
-60341
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2483344
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1132232
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
8605
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-32965
us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
994333
ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
-1939693
ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
2315275
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1707650
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1349506
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2046825
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
71506
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
286562
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24707996
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24546831
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
45014899
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
5000000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
5000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7700
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28857
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
5895
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
173736
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4986405
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40217492
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
30520835
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
73104
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
62724
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
111377
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30593939
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
174101
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10872348
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-64590222
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87125600
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22535378
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
86164
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
104956
CY2019Q1 ovid Gross Proceeds From Issuance Of Stock
GrossProceedsFromIssuanceOfStock
33000000
CY2019Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
30500000
CY2019Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
47361966
CY2019Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
47361966
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
36489618
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
36489618
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
5012863
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1829
CY2019Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
0
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
5000000
CY2019Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
us-gaap Depreciation
Depreciation
19000
us-gaap Depreciation
Depreciation
15000
CY2019Q2 us-gaap Depreciation
Depreciation
9000
CY2018Q2 us-gaap Depreciation
Depreciation
9000
CY2019Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
271000
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
392000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
127000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
36000
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
60000
CY2018Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
19000
CY2019Q2 ovid Clinical Trials Accrual Current
ClinicalTrialsAccrualCurrent
3729260
CY2018Q4 ovid Clinical Trials Accrual Current
ClinicalTrialsAccrualCurrent
1352133
CY2019Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1062481
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1595950
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2779021
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
579198
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
772785
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
168798
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
184923
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each share held
CY2019Q1 ovid Maximum Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates
MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates
0.0999
CY2019Q1 ovid Maximum Allowable Voting Right Percentage Of Outstanding Common Stock Holders
MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders
0.1499
CY2019Q1 ovid Payment Of Share Issuance Expenses By Persons Owning Ten Percent Or More Of Common Stock
PaymentOfShareIssuanceExpensesByPersonsOwningTenPercentOrMoreOfCommonStock
0
us-gaap Dividend Payment Restrictions Schedule Description
DividendPaymentRestrictionsScheduleDescription
No dividends on the common stock shall be declared and paid unless dividends on the Preferred Stock have been declared and paid.
us-gaap Dividends
Dividends
0
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1251907
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1844206
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2894448
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3639173
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4714383
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1865715
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
663154
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5916944
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2902840
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.10
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.50
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M20D
ovid Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
P9Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M13D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y8M19D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
153485
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
142994
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
115687
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M24D
us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
0
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0

Files In Submission

Name View Source Status
0001564590-19-030178-index-headers.html Edgar Link pending
0001564590-19-030178-index.html Edgar Link pending
0001564590-19-030178.txt Edgar Link pending
0001564590-19-030178-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ovid-10q_20190630.htm Edgar Link pending
ovid-20190630.xml Edgar Link completed
ovid-20190630.xsd Edgar Link pending
ovid-20190630_cal.xml Edgar Link unprocessable
ovid-20190630_def.xml Edgar Link unprocessable
ovid-20190630_lab.xml Edgar Link unprocessable
ovid-20190630_pre.xml Edgar Link unprocessable
ovid-ex311_9.htm Edgar Link pending
ovid-ex312_6.htm Edgar Link pending
ovid-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending